Bibliography

Export 16 results:
Filters: Author is Anderlini,P.  [Clear All Filters]
2013
Pulsipher MA, Chitphakdithai P, Logan BR, Shaw BE, Wingard JR, Lazarus HM, et al. Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. Blood. 2013;121(1):197.
2009
Pulsipher MA, Chitphakdithai P, Miller JP, Logan BR, King RJ, Rizzo JD, et al. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood. 2009;113(15):3604-11.
2008
McCullough J, Kahn J, Adamson J, Anderlini P, Benjamin R, Confer D. Hematopoietic growth factors-use in normal blood and stem cell donors: clinical and ethical issues. Transfusion. 2008;48:2008-2025.
2003
Hong DS, Jacobson KL, II R, de Lima M, Anderlini P, Fuller GN, et al. West Nile encephalitis in 2 hematopoietic stem cell transplant recipients: case series and literature review. Clin Infect Dis. 2003;37(8):1044-9.
2002
Anderlini P, Chan FA, Champlin RE, Korbling M, Strom SS. Long-term follow-up of normal peripheral blood progenitor cell donors treated with filgrastim: No evidence of increased risk of leukemia development. Bone Marrow Transplant. 2002;30:661-663.
Esmaeli B, Ahmadi MA, Kim S, Onan H, Korbling M, Anderlini P. Marginal keratitis associated with administration of filgrastim and sargramostim in a healthy peripheral blood progenitor cell donor. Cornea. 2002;21(6):621-2.
2001
Korbling M, Giralt S, Khouri I, Mirza N, Donato M, Anderlini P, et al. Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresis. Journal of Clinical Apheresis. 2001;16(2):82-7.
Anderlini P, Rizzo JD, Nugent ML, Schmitz N, Champlin RE, Horowitz MM. Peripheral blood stem cell donation: An analysis from the international bone marrow transplant registry (IBMTR) and eurpoean group for blood and marrow transplant (EBMT) databases. Bone Marrow Transplant. 2001;27:689-692.
1999
Anderlini P, Donato M, Chan KW, Huh YO, Gee AP, Lauppe MJ, et al. Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience. Transfusion. 1999;39(6):555-60.
Przepiorka D, Smith TL, Folloder J, Khouri I, Ueno NT, Mehra R, et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 1999;94(4):1465-70.
1998
Anderlini P, Przepiorka D, Körbling M, Champlin R. Blood stem cell procurement: donor safety issues. Bone Marrow Transplant. 1998;21 Suppl 3:S35-9.
1997
Anderlini P, Körbling M, Dale D, Gratwohl A, Schmitz N, Stroncek D, et al. Allogeneic blood stem cell transplantation: considerations for donors. Blood. 1997;90(3):903-8.
1996
Anderlini P, Przepiorka D, Seong D, Miller P, Sundberg J, Lichtiger B, et al. Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures.[Erratum appears in Transfusion 1997 Jan;37(1):109]. Transfusion. 1996;36(7):590-5.
Korbling M, Anderlini P, Durett A, Maadani F, Bojko P, Seong D, et al. Delayed effects of rhG-CSF mobilization treatment and apheresis on circulating CD34+ and CD34+ Thy-1dim CD38- progenitor cells, and lymphoid subsets in normal stem cell donors for allogeneic transplantation. Bone Marrow Transplantation. 1996;18(6):1073-9.
Anderlini P, Przepiorka D, Seong D, Champlin R, Korbling M. Transient neutropenia in normal donors after G-CSF mobilization and stem cell apheresis. British Journal of Haematology. 1996;94(1):155-8.
1994
Anderlini P, Przepiorka D, Luna M, Langford L, Andreeff M, Claxton D, et al. Acanthamoeba meningoencephalitis after bone marrow transplantation. Bone Marrow Transplant. 1994;14(3):459-61.